Cognitive Behavioural Therapy for Insomnia (CBT-I) is the gold-standard treatment for chronic insomnia in adults, supported by extensive clinical evidence and recommended by international and Australian sleep medicine guidelines. The challenge in Australian clinical practice in 2026 is access. There remain insufficient trained CBT-I clinicians to meet the demand, particularly outside the major cities.

The current state of CBT-I in Australia

A growing but still limited number of Australian clinical psychologists are formally trained in CBT-I. The sleep psychology workforce is concentrated in Sydney, Melbourne, and Brisbane, with smaller numbers in Adelaide, Perth, and a handful of regional centres. Wait times for an initial appointment with a CBT-I trained psychologist in 2026 range from several weeks in well-served metropolitan areas to many months in regional locations.

The Medicare rebate position has not meaningfully changed in 2026 for psychological services delivered for insomnia. Patients can access subsidised treatment under a Mental Health Care Plan in some specific cases, but the rebate is constrained and not all patients with insomnia have a co-occurring mental health condition that supports the plan.

Digital CBT-I

Digital CBT-I — automated or partially automated CBT-I delivered through a website or app — has continued to mature. The clinical evidence supporting some specific digital CBT-I products is reasonably strong for mild to moderate insomnia. Australian sleep clinics increasingly use digital CBT-I as a first-line tool for patients who cannot easily access in-person therapy, or as adjunctive support.

The limitations of digital CBT-I are well understood. Patient adherence to the digital program is the main constraint. Patients with severe insomnia, with significant co-morbid mental health conditions, or with specific complicating factors (irregular shift work, parental sleep disruption, chronic pain) tend to need human clinician involvement.

The pharmacological context

Pharmacological treatment for insomnia in Australian clinical practice remains a mixed picture in 2026. The traditional benzodiazepine and Z-drug options continue to be prescribed despite the long-standing guidelines recommending non-pharmacological approaches as first-line. Newer dual orexin receptor antagonists are available and increasingly prescribed for specific patients but are not the dominant treatment in volume terms.

The clinical position remains that pharmacological treatment is appropriate for some patients in some contexts but is not a long-term solution for most patients with chronic insomnia, and that CBT-I should be the first-line treatment where access permits.

The workforce question

The under-supply of CBT-I trained clinicians in Australia in 2026 is a recognised workforce issue. Several universities now include CBT-I training in their clinical psychology programs, and post-graduate professional development courses in CBT-I are running in most states. The pipeline is improving but the workforce is not yet large enough to meet the demand.

The Australasian Sleep Association and several university research groups continue to advocate for more workforce development in this space. Progress is real but slow.

The practical position for patients

For Australian adults with chronic insomnia in 2026, the practical pathway is: speak to a GP, request a referral to a sleep physician or directly to a CBT-I trained psychologist where available, consider a clinically-validated digital CBT-I option if in-person access is delayed, and consider pharmacological options only as a short-term bridge under specific clinical guidance.

This is general clinical information. Patients with insomnia or other sleep concerns should consult their GP or a sleep physician.